GHRP-2 and Ipamorelin are both growth hormone secretagogues that stimulate GH release by activating the ghrelin receptor (GHS-R1a) — but they differ critically in receptor selectivity, co-stimulation of cortisol and prolactin, and their pharmacological specificity profiles. GHRP-2 is a first-generation synthetic hexapeptide with strong GH-releasing activity accompanied by dose-dependent stimulation of cortisol and prolactin. Ipamorelin is a third-generation pentapeptide engineered specifically to maximise GHS-R1a selectivity while minimising off-target pituitary hormone release — a selectivity profile that has made it the primary subject of more recent research protocols seeking to isolate the GH-release mechanism.
This article compares the molecular pharmacology, receptor profiles, published evidence bases, and research design considerations for GHRP-2 and Ipamorelin — covering what distinguishes these two compounds beyond the search-term surface, and what that distinction means for rigorous preclinical research design. For research purposes only. Not for human consumption.
Key Takeaways
- Both compounds are GHS-R1a agonists (ghrelin receptor). They stimulate GH release from the anterior pituitary through the same primary receptor — the key difference is what else they do.
-
GHRP-2 (CAS:
158861-67-7; MW: 817.9 Da; 6 amino acids) stimulates GH release but also causes dose-dependent increases in cortisol (ACTH axis) and prolactin — off-target effects that must be controlled for in research designs. -
Ipamorelin (CAS:
170851-70-4; MW: 711.9 Da; 5 amino acids) was specifically engineered for GHS-R1a selectivity — it produces robust GH release with minimal cortisol or prolactin co-stimulation at equivalent doses in published studies. - GHRP-2 is better suited for research investigating the full GH-axis/corticotroph/lactotroph response; Ipamorelin is better suited for research isolating the GH secretagogue mechanism without endocrine co-activation.
- Both available from Pure Grade Labs: GHRP-2 5mg and Ipamorelin 5mg. HPLC-verified. For research purposes only. Not for human consumption.
Source GHRP-2 and Ipamorelin for Research
HPLC-verified purity. Batch-specific COA. Available individually. Research use only. Not for human consumption.
Browse GH Research Peptides →What Are Growth Hormone Secretagogues?
Growth hormone secretagogues (GHS) are a class of synthetic peptides and non-peptide compounds that stimulate GH release from the anterior pituitary gland by activating the ghrelin receptor (GHS-R1a, also known as the growth hormone secretagogue receptor 1a). Endogenous ghrelin — the 28-amino acid orexigenic peptide primarily produced in the gastric fundus — is the natural ligand for GHS-R1a. Synthetic GHS compounds were originally developed to investigate the ghrelin/GH axis and as pharmacological tools for diagnosing GH deficiency states without the cost and variability of exogenous rhGH stimulation testing.
The development of synthetic GHS compounds progressed through three generations: GHRP-6 (first generation, 1980s), GHRP-2 (second generation, 1990s), and Ipamorelin (third generation, late 1990s). Each iteration refined the receptor selectivity profile — aiming to preserve GH-releasing potency while reducing off-target cortisol and prolactin co-stimulation. Both GHRP-2 and Ipamorelin are GHS-R1a agonists; the difference is how selective that agonism is.
GHRP-2: Mechanism and Pharmacological Profile
GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂; CAS: 158861-67-7; MW: 817.9 Da) is a synthetic hexapeptide that activates GHS-R1a with high affinity. In preclinical and human studies, GHRP-2 is a potent GH secretagogue — producing GH pulses that mirror the amplitude of natural pulsatile GH secretion. However, GHRP-2 also activates CRH-independent ACTH release from corticotrophs, leading to dose-dependent increases in plasma cortisol, and stimulates prolactin release from lactotrophs.
These off-target effects are not incidental — they reflect GHRP-2's non-selective engagement with pituitary signalling pathways beyond the GHS-R1a/somatotroph axis. In research terms, this means that any study using GHRP-2 as a GH stimulus must account for concurrent cortisol and prolactin changes as potential confounders. For studies where the question is specifically "what does GH secretagogue-driven GH pulse look like?" without the corticotroph co-activation, GHRP-2 is suboptimal. For studies where the objective is to model the full acute neuroendocrine response to GHS-R1a activation — including the corticotroph and lactotroph components — GHRP-2 is the more informative research tool.
GHRP-2 synergises strongly with GHRH analogues — the combination of GHRP-2 and a GHRH analogue such as CJC-1295 produces GH pulses substantially larger than either compound alone. This synergy operates through complementary receptor activation: GHRP-2 activates GHS-R1a on somatotrophs, while CJC-1295 activates the GHRH receptor (GHRHR) on the same cells — the two pathways converge on cAMP and intracellular calcium signalling to produce additive GH secretion.
Ipamorelin: Mechanism and Selectivity Profile
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂; CAS: 170851-70-4; MW: 711.9 Da) is a third-generation synthetic pentapeptide developed by researchers at Novo Nordisk in the late 1990s. It was designed with the explicit goal of achieving GHS-R1a agonism with minimal cortisol or prolactin co-stimulation — a selectivity goal that distinguished it from GHRP-6 and GHRP-2.
In published rodent and porcine studies, Ipamorelin demonstrates GH-releasing potency comparable to GHRP-2 (at equivalent molar doses) with significantly lower cortisol and prolactin co-stimulation. The landmark selectivity study by Johansen PB et al. (1999, PMID: 10027241) compared GH, ACTH, and cortisol responses following equimolar doses of GHRP-6, GHRP-2, and Ipamorelin in rats and pigs — finding that Ipamorelin achieved similar GH-pulse amplitude to GHRP-2 while producing minimal ACTH/cortisol elevation. This published selectivity profile has driven adoption of Ipamorelin as the preferred GH secretagogue for research designs where GH-specific effects need to be studied in isolation.
Like GHRP-2, Ipamorelin synergises with GHRH analogues. The Ipamorelin + CJC-1295 research combination is one of the most studied GH secretagogue pairings in the published literature, with both compounds operating via mechanistically complementary (GHS-R1a vs GHRHR) but non-redundant receptor pathways.
Research Context
Dr. Sigrid Andersen, an endocrinology researcher at a Scandinavian university, originally designed her GH pulsatility study using GHRP-2 as the GH stimulus. After her research group raised concerns about cortisol co-activation confounding the downstream GH-IGF-1 axis readouts, she switched to Ipamorelin for the primary study arm — running GHRP-2 as a separate comparison arm to characterise the cortisol co-activation signal. The two-arm design produced cleaner mechanistic data than either compound alone would have: she could compare the GH response in isolation (Ipamorelin arm) versus the full neuroendocrine response (GHRP-2 arm) directly.
GHRP-2 vs Ipamorelin: Pharmacological Comparison
| Property | GHRP-2 | Ipamorelin |
|---|---|---|
| CAS Number | 158861-67-7 |
170851-70-4 |
| Sequence Length | 6 amino acids (hexapeptide) | 5 amino acids (pentapeptide) |
| Molecular Weight | 817.9 Da |
711.9 Da |
| Primary Receptor | GHS-R1a (ghrelin receptor) | GHS-R1a (ghrelin receptor) |
| GH Release Potency | High — potent somatotroph activation | High — comparable to GHRP-2 at equimolar doses |
| Cortisol Co-Stimulation | Significant — dose-dependent ACTH/cortisol elevation | Minimal — <0.5x cortisol response vs GHRP-2 at equivalent GH dose (Johansen 1999) |
| Prolactin Co-Stimulation | Moderate — lactotroph co-activation observed | Minimal — selective GHS-R1a agonism minimises lactotroph effect |
| Generation | 2nd generation GHS | 3rd generation GHS |
| GHRH Synergy | Yes — strong synergy with CJC-1295 | Yes — well-established CJC-1295 + Ipamorelin combination in literature |
| Best Suited For | Full neuroendocrine GHS-R1a response modelling; GH + cortisol axis studies | Isolated GH secretion studies; research requiring selective GH pulse without corticotroph confounding |
Published Evidence Base
Ipamorelin Selectivity: The Johansen 1999 Study
The foundational selectivity study for Ipamorelin is Johansen PB, Nowak J, Skjaerbaek C et al. (1999), published in the Journal of Endocrinology. This study directly compared GH, ACTH, and cortisol responses to equimolar intravenous doses of GHRP-6, GHRP-2, and Ipamorelin in rats and pigs. The key finding: Ipamorelin produced equivalent GH pulse amplitude to GHRP-2 while generating less than 10% of the ACTH/cortisol response. This selectivity finding has been the primary reference for subsequent research protocols choosing Ipamorelin for GH-specific investigation. PMID: 10027241. DOI: 10.1677/joe.0.1600035
GHRP-2 in Human GH Stimulation Studies
GHRP-2 has been investigated in human diagnostic studies as a GH stimulation tool in GH-deficient patients, with research demonstrating robust GH release across adult and paediatric populations. Published studies (including Bowers CY et al., 1994, and subsequent clinical groups) validated GHRP-2 as a reliable pharmacological GH stimulus. The co-occurring cortisol elevation was documented across these studies and is a well-characterised property of GHRP-2's off-target receptor engagement. PMID: 8174450. DOI: 10.1210/jcem.78.6.8174450
CJC-1295 + Ipamorelin Combination Research
The research combination of CJC-1295 (GHRH analogue, GHRHR agonist) with Ipamorelin (GHS-R1a agonist) exploits the complementary receptor pathways to produce supra-additive GH secretion. Both receptors converge on cAMP/PKA and intracellular calcium signalling in somatotrophs — activating both simultaneously produces a larger GH pulse than either alone. Teichman SL et al. (2006, PMID: 16822960) published the foundational pharmacokinetic/pharmacodynamic study on CJC-1295, laying the framework for subsequent combination protocol research.
Research Context
A research pharmacologist at a UK CRO was asked to select between GHRP-2 and Ipamorelin for a rat model studying the relationship between pulsatile GH secretion and downstream IGF-1 production in muscle. The choice: Ipamorelin, precisely because the cortisol co-activation from GHRP-2 would independently activate glucocorticoid receptors in muscle tissue — a confounder for the IGF-1/muscle protein synthesis endpoints being measured. The selectivity profile of Ipamorelin allowed the IGF-1 response to be attributed to the GH pulse without the cortisol interference term in the model.
Research Design Considerations
The choice between GHRP-2 and Ipamorelin in a research protocol is not a quality question — both are valid, well-characterised GHS-R1a agonists. It is a study design question: what is the question being asked, and which compound's pharmacological profile most cleanly answers it?
Choose GHRP-2 when:
The research question involves the full neuroendocrine response to GHS-R1a activation, including the corticotroph (ACTH/cortisol) and lactotroph (prolactin) components. Also appropriate for comparative studies characterising differences between GHS generations, or when historical comparison with the substantial GHRP-2 preclinical and human literature is valuable.
Choose Ipamorelin when:
The research question is specifically about GH pulse dynamics, GH-IGF-1 axis signalling, or downstream effects of GH secretion — and cortisol co-activation would confound the endpoints. Ipamorelin is the preferred tool for studies where the objective is to model selective GHS-R1a/somatotroph activation without multi-hormone co-activation.
Use both in comparative protocols:
For research characterising GHS generation differences or validating selectivity claims across models, using both GHRP-2 and Ipamorelin in parallel arms provides the pharmacological comparison data necessary to interpret selectivity-driven experimental variables. Pure Grade Labs supplies both for batch-matched parallel research protocols.
Research Context
A postgraduate student at a Welsh university conducting her PhD on GH secretagogue pharmacology in aged rats ordered GHRP-2 and Ipamorelin from Pure Grade Labs for a three-arm study (GHRP-2, Ipamorelin, vehicle control) in 20-month-old Sprague-Dawley rats. Her primary outcome was the GH pulse area-under-the-curve at 15, 30, 60, and 120 minutes post-administration. Secondary outcomes included plasma cortisol, IGF-1, and body composition at 8 weeks. The batch COA provided for both compounds was a prerequisite for her institutional ethics submission, which required documented purity for the compounds being used in the animal study protocol.
GHRP-2 and Ipamorelin — Research-Grade Quality
Both compounds HPLC-verified with batch COA. Available for batch-matched comparative research protocols. Not for human consumption.
Browse GH Secretagogue Research Peptides →Frequently Asked Questions
Cited Research
- Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106–13. PMID: 10027241. DOI: 10.1054/ghir.1999.9954
- Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 1991;128(4):2027–35. PMID: 1849136. DOI: 10.1210/endo-128-4-2027
- Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445–60. PMID: 9167043. DOI: 10.1530/eje.0.1360445
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PMID: 16822960. DOI: 10.1210/jc.2005-1536
- Popovic V, Leal A, Micic D, et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet. 2000;356(9236):1137–42. PMID: 11030300. DOI: 10.1016/S0140-6736(00)02755-X
GHRP-2 and Ipamorelin — Available for Research
Both compounds available individually with HPLC verification and batch COA. Research use only. Not for human consumption.
Browse All Growth Hormone Research Peptides →Research Use Only. GHRP-2 and Ipamorelin are supplied by Pure Grade Labs strictly as research chemicals for laboratory use only. Not for human consumption. No medical claims are made. This article is provided for educational purposes only and does not constitute medical advice, prescribing information, or a recommendation to administer any compound to humans or animals. Pure Grade Labs accepts no liability for misuse of supplied research chemicals.